Final Program

270 TUESDAY • MAY 17
P474
P475
Facilitator:
P476
The Measurement of Cough Response to Bronchoconstriction
Induced by Methacholine: An Examination Using the
Astograph Method/J. Hara, M. Fujimura, T. Sakai, N. Ohkura, A.
Okazaki, S. Watanabe, Y. Ishiura, K. Kasahara, Kanazawa, Japan,
p.A5167
Use of Non-Steroidal Infiammatory Drugs (NSAID) in
Post-Infectious Cough/A. Zanasi, F. Saibene, L. Lanata, M.
Mazzolini, Bologna, Italy, p.A5168
S. Stowasser, MD, Rhein, Germany
What Is the Optimum Endpoint for the Capsaicin Cough
Challenge?/R.D. Turner, S.S. Birring, G.H. Bothamley, London,
United Kingdom, p.A5169
P477 Middle Mediastinal Ectopic Thymic Hyperplasia/K. Hanlon, A.
Staricco, Detroit, MI, p.A5170
P478
P479
P480
P481
An Unfortunate Mimicker of Sarcoidosis in a 36 Year Old
Man/K. Waksmundzki, M. Stefanski, M. Joshi, J.W. Toth, L.J. Van
Scoy, Hershey, PA, p.A5171
Endobronchial Lipoma: A Rare and Benign Lung Tumor/M.M.
Herrera, K.G. Mayhall, S. Dolan, Milwaukee, WI, p.A5172
Pneumorachis: An Unusual Sequela of Spontaneous
Pneumomediastinum/A. Bhatt, S. Suliman, V. Nidadavolu, K.
El-Kersh, Louisville, KY, p.A5173
Spontaneous Lung Herniation Following Cough/N.
Thiruchelvam, N. Alappan, Cleveland, OH, p.A5174
P482 An In Vitro Model of Airway Aspiration?/A.H. Morice, L.
Sadofsky, S. Hart, Cottingham, United Kingdom, p.A5175
P1242
P1243
P1244
P1245
P1246
P1247
Lung-Function Profile Before and After the First Moderate to
Severe Exacerbation During the WISDOM Study/E. Wouters, H.
Magnussen, R. Rodriguez-Roisin, K. Tetzlaff, S. Bell, P.M.
Calverley, Maastricht, Netherlands, p.A5179
Roflumilast Initiated at Onset of Acute Exacerbation of COPD
Enhances Lung Function Recovery: Results from the
Randomised, Double-Blind, Placebo-Controlled, Parallel-Group
Trial, Treatment with Roflumilast at ExAcerbaTion (TREAT)/A.J.
Mackay, A.R.C. Patel, R. Singh, R. Sapsford, G.C. Donaldson, N.
Prasad, U. Goehring, K. Nip, J.A. Wedzicha, London, United
Kingdom, p.A5180
Reduction of Airway Inflammation with Roflumilast Initiated at
Onset of Acute Exacerbation of COPD: Results from the
Randomised, Double-Blind, Placebo-Controlled, Parallel-Group
Trial, Treatment with Roflumilast at ExAcerbaTion (TREAT)/A.J.
Mackay, A.R.C. Patel, R. Singh, R. Sapsford, G.C. Donaldson, N.
Prasad, U. Goehring, K. Nip, J.A. Wedzicha, London, United
Kingdom, p.A5181
Role of Osteopontin in Differential Diagnosis of Acute
Exacerbations of COPD from Pneumonia/T. Ozlu, S. Gunaydin,
S. Ozsu, Y. Abul, A. Orem, Trabzon, Turkey, p.A5182
Clinical Significance of Isolation of Aspergillus spp. During
Acute Exacerbation of Chronic Obstructive Lung Disease/M.
Patout, E. Lhuillier, A. Benattia, L. Favennec, L. Thiberville, J.-F.
Muir, A. Cuvelier, Bois-Guillaume, France, p.A5183
Bronchodilator Response to Anticholinergic Agent Is
Associated with Exacerbation in Patients with COPD/S. Konno,
H. Makita, M. Suzuki, K. Shimizu, H. Kimura, M. Nishimura,
Sapporo, Japan, p.A5184
C47
THEMATIC POSTER SESSION
COPD: EXACERBATIONS
9:00 a.m. - 4:15 p.m. MOSCONE CENTER
Viewing: Posters will be on display for entire session.
Area L, Hall D (North Building, Lower Level)
Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators
Facilitator:
P1239
P1240
P1241
N.A. Hanania, MD, MS, Houston, TX
Procalcitonin Level Based Care in Hospitalized Patients with
Acute Exacerbations of COPD/N. Menon, B.M. Walsh, M.
Vitunac, C. Francis, D. Francis, R. Evans, P.F. Simonelli, Danville,
PA, p.A5176
Outcomes Following Virus and Non-Virus Associated Acute
Exacerbations of COPD/B.M. Walsh, N. Menon, D. Francis, C.
Francis, P.F. Simonelli, Danville, PA, p.A5177
Prevalence of Bacterial and Viral Infections in Acute
Exacerbation of Chronic Obstructive Pulmonary Disease in
Single Center in South Korea/J. Choi, K.H. Min, S. Chung, J.Y.
Oh, J.K. Sim, G.Y. Hur, S.Y. Lee, K.H. Kang, J.J. Shim, Seoul,
Korea, Republic of, p.A5178
Facilitator:
P1248
P1249
P1250
P1251
P1252
S.D. Aaron, MD, Ottawa, Canada
Eosinophilia Is Common in COPD Exacerbations and
Associated with Non-Infectious Aetiology/M.I. MacDonald, C.R.
Osadnik, M. Qiu, S. Vasanthakumar, P. King, P.G. Bardin,
Melbourne, Australia, p.A5185
Correlation Between Symptoms Pattern and Future
Exacerbations: A Post-Hoc Analysis from The SPARK
Study/J.A. Wedzicha, K. Mezzi, R. Fogel, G. Bader, D. Banerji,
London, United Kingdom, p.A5186
Are Viral Infections Associated to Severe Exacerbation in
Chronic Obstructive Pulmonary Disease (COPD) Due to
Biomass Exposure?/P. Paulin-Prado, N. Bautista-Felix, M.
Velazquez-Uncal, O. Perez, A. Nolasco, F. Dueñas, R.
Hernandez-Zenteno, F. Flores-Trujillo, A. Velazquez, C. Espinosa
De Los Monteros, C. Sanchez, L. Ochoa-Coutino, R.H. Sansores,
A. Ramirez-Venegas, Mexico, Mexico, p.A5187
Characterisation of Isolates of Streptococcus Pneumoniae in
Patients with Chronic Obstructive Pulmonary Disease - Is There
a Role for the Pneumococcal Conjugate Vaccine (PCV13)?/
R. Costello, H. McCarthy, M. Jackson, M. Corcoran, M. McElligott, E.
MacHale, I. Sulaiman, H. Humphreys, Dublin, Ireland, p.A5188
Immunoglobulin G Deficiency Increases the Severity and
Frequency of Exacerbations of Chronic Obstructive Pulmonary
Disease/C. Kim, S. Gumus, P. Mulhall, D. Ciccolella, F. Cordova,
Philadelphia, PA, p.A5189
ATS 2016 • San Francisco